Tesamorelin: What the Evidence Actually Shows

Tesamorelin occupies an unusual spot in this site's corpus: unlike sermorelin, CJC-1295, or ipamorelin — the other growth-hormone-releasing-hormone (GHRH) compounds most often discussed alongside it — tesamorelin is a real, currently-marketed, FDA-approved biologic, sold under the brand name Egrifta. A live openFDA Drugs@FDA check confirms BLA022505, sponsored by Theratechnologies, originally approved November 10, 2010¹. That's a meaningfully different regulatory starting point than most of this site's GH-axis coverage, and it's worth understanding tesamorelin on its own terms before comparing it to anything else.

What it's actually approved for — and what it isn't

Egrifta SV's current FDA label states its indication in exactly these terms: "EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy²." The same label is direct about two limits worth stating plainly. First: "Long-term cardiovascular safety of EGRIFTA SV has not been established²." Second, a distinction this site's readers searching for a body-composition or weight-loss drug need up front: "EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect²." This is a narrow, HIV-lipodystrophy-specific approval — not a general anti-aging, longevity, or fat-loss indication, regardless of how it's sometimes marketed off-label.

How it actually works

Tesamorelin's own label describes its mechanism precisely: "In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF²." GRF — growth-hormone-releasing factor, interchangeable with GHRH — is the hypothalamic peptide that signals the pituitary's somatotroph cells to release growth hormone in a pulsatile pattern. Tesamorelin is a synthetic analog of that same 44-amino-acid native hormone, engineered for a longer working duration than the endogenous signal². This is the same broad mechanism class as sermorelin and CJC-1295 — a GHRH-receptor agonist stimulating the body's own GH pulse, not a synthetic GH injection itself — but tesamorelin is the only one of the three with an actual FDA-reviewed efficacy and safety record behind that mechanism.

The pivotal trial: what actually moved, and what didn't

Tesamorelin's approval rests on a pooled analysis of two multicenter, international, randomized, double-blind, placebo-controlled Phase 3 trials — 806 ART-treated HIV patients with excess abdominal fat, randomized 2:1 to tesamorelin 2 mg or placebo, injected subcutaneously once daily³. At week 26, the primary endpoint — visceral adipose tissue measured by CT scan — fell by 24 ± 41 cm² in the tesamorelin group versus a 2 ± 35 cm² increase in the placebo group (P<.001), a -15.4% treatment effect³. Two findings worth naming precisely rather than rounding into a generic "it worked": subcutaneous fat did NOT change significantly between groups (P=.08) — this is a visceral-fat-specific effect, not a general body-fat reduction³. And the metabolic side effects moved favorably alongside the fat change: triglycerides fell 37 ± 139 mg/dL versus a 6 mg/dL rise on placebo (P<.001), and the cholesterol-to-HDL ratio improved by -0.18 versus +0.18 on placebo (P<.001)³ — a real, statistically significant metabolic benefit specific to the HIV-lipodystrophy population this trial actually studied, not a claim this article extends to any other population.

A real safety signal worth naming, in real numbers

A live openFDA FAERS check for tesamorelin returns 10 total adverse-event reports naming the drug, with depression (3 reports), acute kidney injury (2), anxiety (2), feeling abnormal (2), lipodystrophy acquired (2), and weight decreased (2) among the most frequent reaction terms⁴. Ten total reports is too small a sample to compute a meaningful incidence rate or draw a causal conclusion from — the same caveat this site applies to every other compound's FAERS count — but it's reported here rather than omitted, consistent with this corpus's standing rule to state what the data shows rather than what would be more flattering to leave out. Our dedicated tesamorelin side-effects article covers the trial-reported adverse-event data in full detail; this is the FAERS spontaneous-report supplement to that, not a replacement for it.

Not the same drug as sermorelin — a real regulatory gap, not a technicality

Sermorelin has no current FDA-approved product at all — our sermorelin dosage article covers exactly why. Tesamorelin does, which is why this article can quote an actual FDA label and an actual pivotal Phase 3 trial where the sermorelin-focused articles elsewhere on this site have to work from older, discontinued-product data instead. That gap is real and worth understanding before treating the two compounds as interchangeable GH-axis options — see our direct sermorelin-vs-tesamorelin comparison for the full side-by-side.

What this means if you're considering it

Tesamorelin is a real, FDA-approved biologic for a specific, narrow indication — reducing visceral abdominal fat in HIV-infected adults with lipodystrophy — backed by a genuine 806-patient pooled Phase 3 program, not by anecdote or a compounding pharmacy's marketing copy. It is not an approved weight-loss drug, and its label says so directly. If you already have a prescribed tesamorelin dose, our reconstitution calculator runs the vial-to-syringe arithmetic; if you're still working out the dose itself, our tesamorelin dosing article reports exactly what both current labels specify.